{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:15:49Z","timestamp":1787915749706,"version":"build-2784847793"},"reference-count":62,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"provided by Rob Furlong and Kerry Dechant on behalf of Content Ed Net"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2021,7,3]]},"DOI":"10.1080\/14737175.2021.1935879","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T07:24:41Z","timestamp":1623050681000},"page":"755-778","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years\u201d accumulated evidence from clinical trials"],"prefix":"10.1080","volume":"21","author":[{"given":"Jos\u00e9 Mar\u00eda","family":"Prieto Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Jefe del Servicio de Neurolog\u00eda\/Neurology Service Head, Hospital Cl\u00ednico Universitario, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vila Silv\u00e1n","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Almirall S.A., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2005.08.026"},{"key":"cit0002","unstructured":"Sativex Oromucosal Spray. Summary of product characteristics. GW Pharma Ltd; August 2020. [cited 2021 Jan 28]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/602\/smpc#gref"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01639.x"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1179\/016164109X12590518685660"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03328.x"},{"key":"cit0006","unstructured":"Sativex\u00ae oromucosal spray. Summary of product characteristics. Neopharm Scientific Ltd; September 2012. [cited 2021 Jan 28]. Available from: http:\/\/www.pharmaline.co.il\/images\/newsletterregistration\/neopharm\/2012\/03092012\/sativex_dr.pdf"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1297"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2021.1904896"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1177\/2049463717710042"},{"key":"cit0010","first-page":"2","volume":"1","author":"Vachov\u00e1 M","year":"2014","journal-title":"J Mult Scler"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.14548"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1159\/000367619"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7866-5"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-016-2780-x"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2017-0055"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13623"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1443-y"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1029"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1191\/0269215503cr581oa"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1191\/1352458504ms1082oa"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181633497"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511419700"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.17653\/2374-9091.SS0005"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7878-1"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2018.1481066"},{"key":"cit0026","unstructured":"EU Clinical Trials Register. Sativex\u00ae as add-on therapy vs. further optimised first-line ANTispastics the SAVANT trial; 2015. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2015-004451-40"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1177\/1352458505070618"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6634-z"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2017-0056"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1159\/000445943"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30406-X"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.013"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000176753.45410.8b"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.08.028"},{"key":"cit0035","unstructured":"ClinicalTrials.gov. A double blind, randomized, placebo controlled, parallel group study of Sativex in the treatment of subjects with pain due to diabetic neuropathy; 2012. [cited 2021 Jan 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00710424"},{"key":"cit0036","unstructured":"ClinicalTrials.gov. A study to evaluate the effects of cannabis-based medicine in patients with pain of neurological origin; 2012. Available from: http:\/\/ClinicalTrials.gov\/show\/NCT01606176"},{"key":"cit0037","unstructured":"ClinicalTrials.gov. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury; 2012; [cited 2021 Jan 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01606202"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6739-4"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.02.018"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1002\/j.1532-2149.2013.00445.x"},{"key":"cit0041","unstructured":"ClinicalTrials.gov. A study to determine the maintenance of effect after long-term treatment of Sativex\u00ae in subjects with neuropathic pain. [cited 2021 Jan 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00713817"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.09.013"},{"key":"cit0043","unstructured":"ClinicalTrials.gov. A study to compare the safety and tolerability of Sativex\u00ae in patients with neuropathic pain; 2012. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00713323"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7502-9"},{"issue":"6","key":"cit0045","first-page":"1145","volume":"17","author":"Russo M","year":"2016","journal-title":"Pain Med"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.3390\/medicines5030059"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.06.008"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.01.003"},{"key":"cit0049","unstructured":"ClinicalTrials.gov. Sativex\u00ae for relieving persistent pain in patients with advanced cancer (SPRAY III). [cited 2021 Jan 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01361607"},{"key":"cit0050","unstructured":"ClinicalTrials.gov. A two-part study of Sativex\u00ae oromucosal spray for relieving uncontrolled persistent pain in patients with advanced cancer. [cited 2021 Jan 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01424566"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2017.09.001"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.07.014"},{"key":"cit0053","unstructured":"ClinicalTrials.gov. Long term safety of Sativex oromucosal spray (Sativex\u00ae; nabiximols) as adjunctive therapy in patients with uncontrolled persistent chronic cancer related pain. 2018; [cited 2021 Jan 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01337089"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei183"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S240011"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.12"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318212ab0c"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.3485"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6358"},{"key":"cit0060","unstructured":"Valeant Pharmaceuticals International Inc. Nabilone (Cesamet\u00ae) capsules: US prescribing information; 2015. [cited 2021 Jan 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/018677s011lbl.pdf"},{"key":"cit0061","unstructured":"Insys Therapeutics Inc. Dronabinol (Syndros\u00ae) oral solution: US prescribing information; 2018. [cited 2021 Jan 28]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c2bc83c1-f9fe-11e2-b778-0800200c9a66"},{"key":"cit0062","unstructured":"Greenwich Biosciences Inc. Cannabidiol (Epidiolex\u00ae) oral solution: US prescribing information; 2018. [cited 2021 Jan 28]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2021.1935879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T11:01:11Z","timestamp":1628766071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2021.1935879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,3]]}},"alternative-id":["10.1080\/14737175.2021.1935879"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2021.1935879","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}